美國醫生愛德華‧亞特瓦特日前通過網絡展示了自己的收藏品。他在過去30年間，收集了來自世界上100多個國家的6200多張艾滋病海報，成為世界上最大的艾滋病海報收藏家。
http://news.backchina.com/viewnews-170214-big5.html
Showing posts with label 愛滋病. Show all posts
Showing posts with label 愛滋病. Show all posts
1.12.11
美國醫生展出其30年收藏的6200張愛滋病海報(30圖片)
京港台時間︰2011/12/1 消息來源︰網易
美國醫生愛德華‧亞特瓦特日前通過網絡展示了自己的收藏品。他在過去30年間，收集了來自世界上100多個國家的6200多張艾滋病海報，成為世界上最大的艾滋病海報收藏家。
http://news.backchina.com/viewnews-170214-big5.html
美國醫生愛德華‧亞特瓦特日前通過網絡展示了自己的收藏品。他在過去30年間，收集了來自世界上100多個國家的6200多張艾滋病海報，成為世界上最大的艾滋病海報收藏家。
http://news.backchina.com/viewnews-170214-big5.html
全球逾三千萬人帶愛滋病毒
明報
12月1日是世界愛滋病日，聯合國30日發表報告顯示，全球3400萬人攜帶愛滋病毒。
世界衛生組織、聯合國兒童基金會和愛滋病規劃署30日聯合發布的《2011年全球應對愛滋病行動進展報告》顯示，2010年底，約有3400萬人攜帶愛滋病毒。
在12月1日世界愛滋病日到來之際，世界衛生組織、聯合國兒童基金會和愛滋病規劃署聯合發布的全球應對愛滋病行動的最新進展報告顯示，全球抗愛滋工作取得了明顯進展。
報告指出，2010年，全世界大約有270萬人新感染了愛滋病毒。2005年全球愛滋病死亡人數高達220萬人，此後，死亡人數持續下降，到2010年，降至大約180萬人。
報 告顯示，新增感染病例在過去十年間減少了15%，與愛滋病相關的死亡人數在五年中下降了22%。自2003年以來，中低收入國家共有665萬人接受抗逆轉 錄病毒治療，也就是說，需要獲得治療的人當中有半數能夠獲得治療。在所有攜帶愛滋病毒的孕婦中，有48%能夠獲得有效的抗逆轉錄病毒治療，以防止病毒在母 嬰之間傳播。
報告指出，2010年，受全球金融和經濟危機影響，捐助資金出現大幅減少，與2009年相比減少了10%。報告預計，在2015年以前，每年需要220億至240億美元，每年的資金缺口大約為70億美元。
http://hk.news.yahoo.com/全球逾三千萬人帶愛滋病毒-003036971.html
12月1日是世界愛滋病日，聯合國30日發表報告顯示，全球3400萬人攜帶愛滋病毒。
世界衛生組織、聯合國兒童基金會和愛滋病規劃署30日聯合發布的《2011年全球應對愛滋病行動進展報告》顯示，2010年底，約有3400萬人攜帶愛滋病毒。
在12月1日世界愛滋病日到來之際，世界衛生組織、聯合國兒童基金會和愛滋病規劃署聯合發布的全球應對愛滋病行動的最新進展報告顯示，全球抗愛滋工作取得了明顯進展。
報告指出，2010年，全世界大約有270萬人新感染了愛滋病毒。2005年全球愛滋病死亡人數高達220萬人，此後，死亡人數持續下降，到2010年，降至大約180萬人。
報 告顯示，新增感染病例在過去十年間減少了15%，與愛滋病相關的死亡人數在五年中下降了22%。自2003年以來，中低收入國家共有665萬人接受抗逆轉 錄病毒治療，也就是說，需要獲得治療的人當中有半數能夠獲得治療。在所有攜帶愛滋病毒的孕婦中，有48%能夠獲得有效的抗逆轉錄病毒治療，以防止病毒在母 嬰之間傳播。
報告指出，2010年，受全球金融和經濟危機影響，捐助資金出現大幅減少，與2009年相比減少了10%。報告預計，在2015年以前，每年需要220億至240億美元，每年的資金缺口大約為70億美元。
http://hk.news.yahoo.com/全球逾三千萬人帶愛滋病毒-003036971.html
16.9.11
Merck疫苗的科學家Dr. Maurice Hilleman承認SV40，愛滋病和癌症病毒疫苗已經存在
本網站所載資料只供參考，如有更改、恕不另行通知。本網站並不保證該等資料之準確性及完整性。對於使用或依賴本網站資料，或因經本網站連結所取得之其他互聯網資料，所引致的任何損失，本網站概不負責。
http://www.activistpost.com/2011/09/merck-vaccine-scientist-dr-maurice.html
12.9.11
發光貓和梅奧診所抗擊愛滋病等疾病
Mayo Clinic researchers have developed a genome-based immunization strategy to fight feline AIDS and illuminate ways to combat human HIV/AIDS and other diseases.
Credit: Mayo Clinic
Mayo Clinic researchers have developed a genome-based immunization strategy to fight feline AIDS and illuminate ways to combat human HIV/AIDS and other diseases. The goal is to create cats with intrinsic immunity to the feline AIDS virus. The findings -- called fascinating and landmark by one reviewer -- appear in the current online issue of Nature Methods.
Feline immunodeficiency virus (FIV) causes AIDS in cats as the human immunodeficiency virus (HIV) does in people: by depleting the body's infection-fighting T-cells. The feline and human versions of key proteins that potently defend mammals against virus invasion -- termed restriction factors -- are ineffective against FIV and HIV respectively. The Mayo team of physicians, virologists, veterinarians and gene therapy researchers, along with collaborators in Japan, sought to mimic the way evolution normally gives rise over vast time spans to protective protein versions. They devised a way to insert effective monkey versions of them into the cat genome.
"One of the best things about this biomedical research is that it is aimed at benefiting both human and feline health," says Eric Poeschla, M.D., Mayo molecular biologist and leader of the international study. "It can help cats as much as people."
Dr. Poeschla treats patients with HIV and researches how the virus replicates. HIV/AIDS has killed over 30 million people and left countless children orphaned, with no effective vaccine on the horizon. Less well known is that millions of cats also suffer and die from FIV/AIDS each year. Since the project concerns ways introduced genes can protect species against viruses, the knowledge and technology it produces might eventually assist conservation of wild feline species, all 36 of which are endangered.
The technique is called gamete-targeted lentiviral transgenesis -- essentially, inserting genes into feline oocytes (eggs) before sperm fertilization. Succeeding with it for the first time in a carnivore, the team inserted a gene for a rhesus macaque restriction factor known to block cell infection by FIV, as well as a jellyfish gene for tracking purposes. The latter makes the offspring cats glow green.
The macaque restriction factor, TRIMCyp, blocks FIV by attacking and disabling the virus's outer shield as it tries to invade a cell. The researchers know that works well in a culture dish and want to determine how it will work in vivo. This specific transgenesis (genome modification) approach will not be used directly for treating people with HIV or cats with FIV, but it will help medical and veterinary researchers understand how restriction factors can be used to advance gene therapy for AIDS caused by either virus.
The method for inserting genes into the feline genome is highly efficient, so that virtually all offspring have the genes. And the defense proteins are made throughout the cat's body. The cats with the protective genes are thriving and have produced kittens whose cells make the proteins, thus proving that the inserted genes remain active in successive generations.
The other researchers are Pimprapar Wongsrikeao, D.V.M., Ph.D.; Dyana Saenz, Ph.D.; and Tommy Rinkoski, all of Mayo Clinic; and Takeshige Otoi, Ph.D., of Yamaguchi University, Japan. The research was supported by Mayo Clinic and the Helen C. Levitt Foundation. Grants from the National Institutes of Health supported key prior technology developments in the laboratory.
Contacts and sources:
Mayo Clinic researchers have developed a genome-based immunization strategy to fight feline AIDS and illuminate ways to combat human HIV/AIDS and other diseases. The goal is to create cats with intrinsic immunity to the feline AIDS virus. The findings -- called fascinating and landmark by one reviewer -- appear in the current online issue of Nature Methods.
Feline immunodeficiency virus (FIV) causes AIDS in cats as the human immunodeficiency virus (HIV) does in people: by depleting the body's infection-fighting T-cells. The feline and human versions of key proteins that potently defend mammals against virus invasion -- termed restriction factors -- are ineffective against FIV and HIV respectively. The Mayo team of physicians, virologists, veterinarians and gene therapy researchers, along with collaborators in Japan, sought to mimic the way evolution normally gives rise over vast time spans to protective protein versions. They devised a way to insert effective monkey versions of them into the cat genome.
"One of the best things about this biomedical research is that it is aimed at benefiting both human and feline health," says Eric Poeschla, M.D., Mayo molecular biologist and leader of the international study. "It can help cats as much as people."
Dr. Poeschla treats patients with HIV and researches how the virus replicates. HIV/AIDS has killed over 30 million people and left countless children orphaned, with no effective vaccine on the horizon. Less well known is that millions of cats also suffer and die from FIV/AIDS each year. Since the project concerns ways introduced genes can protect species against viruses, the knowledge and technology it produces might eventually assist conservation of wild feline species, all 36 of which are endangered.
The technique is called gamete-targeted lentiviral transgenesis -- essentially, inserting genes into feline oocytes (eggs) before sperm fertilization. Succeeding with it for the first time in a carnivore, the team inserted a gene for a rhesus macaque restriction factor known to block cell infection by FIV, as well as a jellyfish gene for tracking purposes. The latter makes the offspring cats glow green.
The macaque restriction factor, TRIMCyp, blocks FIV by attacking and disabling the virus's outer shield as it tries to invade a cell. The researchers know that works well in a culture dish and want to determine how it will work in vivo. This specific transgenesis (genome modification) approach will not be used directly for treating people with HIV or cats with FIV, but it will help medical and veterinary researchers understand how restriction factors can be used to advance gene therapy for AIDS caused by either virus.
The method for inserting genes into the feline genome is highly efficient, so that virtually all offspring have the genes. And the defense proteins are made throughout the cat's body. The cats with the protective genes are thriving and have produced kittens whose cells make the proteins, thus proving that the inserted genes remain active in successive generations.
The other researchers are Pimprapar Wongsrikeao, D.V.M., Ph.D.; Dyana Saenz, Ph.D.; and Tommy Rinkoski, all of Mayo Clinic; and Takeshige Otoi, Ph.D., of Yamaguchi University, Japan. The research was supported by Mayo Clinic and the Helen C. Levitt Foundation. Grants from the National Institutes of Health supported key prior technology developments in the laboratory.
Contacts and sources:
Subscribe to:
Posts (Atom)